Day: May 28, 2020

TORONTO, May 28, 2020 (GLOBE NEWSWIRE) — Mitchell Cohen, Chief Executive Officer and President of Urbanfund Corp. (TSX-V: UFC) (“Urbanfund” or the “Company”), confirmed today that the Company has filed its financial statements for the three months ended March 31, 2020 (the “Consolidated Financial Statements”) and corresponding Management’s Discussion and Analysis (“MD&A”).BUSINESS OVERVIEW AND STRATEGYBusiness OverviewUrbanfund Corp. is an incorporated entity listed on the TSX Venture Exchange (“TSX-V”) under the symbol UFC. The Company is a reporting issuer in Alberta, British Columbia and Ontario. Urbanfund’s focus is to invest in Canadian real estate and real estate related projects with a focus on a mix of both residential and commercial properties. The Company’s assets are located in Toronto, Brampton, Belleville, Kitchener,...

THE WOODLANDS, Texas, May 28, 2020 (GLOBE NEWSWIRE) — Apergy Corporation (“Apergy”) (NYSE: APY) today announced its shareholders voted at the Special Meeting of Shareholders to approve the issuance of shares of Apergy common stock in connection with the pending combination of the ChampionX business with Apergy through a merger of Athena Merger Sub, Inc., a wholly owned subsidiary of Apergy, with ChampionX Holding Inc., a wholly owned subsidiary of Ecolab Inc. The merger is expected to be completed in the second quarter of this year, subject to remaining closing conditions.“Today marks another important milestone as we move toward closing the ChampionX transaction.  We are pleased with the outcome of today’s Special Meeting and thank our shareholders for their continued support,” said Sivasankaran “Soma” Somasundaram, President and...

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, at 9:00 a.m. ET.  A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90 days following the presentation.About Mersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop...

Press release Regulated information  28 May 2020, 11:00 p.m. CESTIRVINE, CA, and HERSTAL, BELGIUM – 28 May 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the “Company” or “MDxHealth“), a commercial-stage innovative molecular diagnostics company, today held its annual general shareholders’ meeting (“AGM“) and an extraordinary general shareholders’ meeting (“EGM“).The items on the agenda of the AGM included the approval of a number of resolutions relating to the financial year ended on 31 December 2019. There was no attendance quorum for the AGM, and the proposed resolutions that were submitted to meeting were all duly passed.As the required attendance quorum for the EGM was not met, a new EGM will be held on 30 July 2020 (unless decided otherwise by the Company). There will be...

Communiqué de presse Information réglementée 28 mai 2020,  23:00 HECIRVINE, CA, et HERSTAL, BELGIQUE – le 28 mai 2020 – MDxHealth SA (Euronext Brussels: MDXH) (la “Société” ou “MDxHealth“), une société de diagnostic moléculaire innovante en phase de commercialisation, a tenu aujourd’hui son assemblée générale annuelle des actionnaires (“AGA“) et une assemblée générale extraordinaire des actionnaires (“AGE“).Les points à l’ordre du jour de l’AGA comprenaient la proposition d’approbation d’un certain nombre de résolutions relatives à l’exercice social clos le 31 décembre 2019. Il n’y avait pas de quorum de présence pour l’AGA, et les propositions de résolutions qui ont été soumises à l’assemblée ont été dûment adoptées.Etant donné que le...

SAN MATEO, Calif., May 28, 2020 (GLOBE NEWSWIRE) — Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) (the “Company” or “PLUS”), a cannabis branded products company in the U.S., today released its unaudited financial and operational results for the three months ended March 31, 2020, expressed in U.S. dollars. These filings are available for review on the Company’s SEDAR profile at www.sedar.com and on the Canadian Securities Exchange (the “CSE”) website at www.thecse.com.Q1 2020 Financial HighlightsRevenues:  Net revenues climbed to $4.7M in Q1 2020, representing 46% year-over-year growth as compared to Q1 2019 net revenues of $3.2M and 36% quarter-over-quarter growth as compared to Q4 2019 net revenues of $3.5M. The Company continues to see revenue growth driven by its core operations in the California adult-use market, with contributions...

CALGARY, Alberta, May 28, 2020 (GLOBE NEWSWIRE) — Inventronics Limited (“Inventronics” or the “Corporation”) (IVX:TSX Venture), a designer and manufacturer of custom enclosures for the telecommunications, electric transmission, cable television and other industries in North America, today announced its unaudited 2020 Q1 financial results.For the three months ended March 31, 2020, Inventronics reported a net income of $44,000, or 1.0 cents per share, on revenue of $1,044,000 compared to net income of $20,000, or 0.5 cents per share, on revenue of $1,132,000 for the three months ended March 31, 2019. Further information about the financial results of the Corporation can be found in the Corporation’s unaudited interim financial statements for the quarter ended March 31, 2020 and accompanying management’s discussion and...

Les résultats de l’étude de prolongation ouverte (EPO) de l’essai pivot NEURO-TTR publiés dans la revue European Journal of Neurology montrent que les patients traités avec le TEGSEDI® (inotersen) ont bénéficié d’améliorations durables des mesures de l’évolution neuropathique après 39 mois de traitement et d’améliorations cliniquement pertinentes des mesures de la qualité de vie par rapport à l’évolution naturelle de la maladieAucun nouveau signal d’innocuité n’a été identifiéLe TEGSEDI se présente sous forme d’une injection sous-cutanée administrée au domicile du patientBOSTON et CARLSBAD, Californie, 28 mai 2020 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ : AKCA), une filiale à participation majoritaire d’Ionis Pharmaceuticals, Inc., et Ionis Pharmaceuticals,...

Im European Journal of Neurology veröffentlichte Ergebnisse aus der laufenden offenen Verlängerungsstudie (open-label extension, OLE) der zulassungsrelevanten Studie NEURO-TTR belegen, dass die mit TEGSEDI® (Inotersen) behandelten Patienten nach 39 Behandlungsmonaten eine nachhaltige Verbesserung des neuropathischen Krankheitsverlaufs und eine klinisch relevante Verbesserung der Lebensqualitätsparameter gegenüber dem natürlichen Verlauf der Erkrankung aufwiesenEs wurden keine neuen Sicherheitssignale festgestelltTEGSEDI ist eine subkutane Injektion, die zu Hause verabreicht wirdBOSTON und CARLSBAD, Kalifornien, May 28, 2020 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), eine Tochtergesellschaft im Mehrheitsbesitz von Ionis Pharmaceuticals, Inc., und Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) gaben heute die Veröffentlichung...

NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility solutions, announced today it has successfully completed an amendment to its senior, secured credit agreement.  The Company is a party to a syndicated credit facility comprised of an $800 million revolving line of credit and an $800 million amortizing term loan, both of which mature on September 1, 2022.  On March 24, 2020, as a precautionary measure, the Company elected to fully draw on its remaining revolving line of credit adding approximately $300 million of capacity to its balance sheet.  As of April 30, 2020, the Company had in excess of $500 million on its balance sheet. The amendment is expected to enhance financial flexibility as the Company continues to navigate the COVID-19 pandemic, in addition to addressing a scheduled stepdown...